Last reviewed · How we verify
Tyvaso®
Tyvaso®, marketed by Insmed Incorporated, is a respiratory drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Tyvaso® |
|---|---|
| Also known as | Inhaled treprostinil |
| Sponsor | Insmed Incorporated |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension (PHASE2)
- A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
- ADAPT - A Patient Registry of the Real-world Use of Orenitram®
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants (PHASE1)
- TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) (PHASE4)
- Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH (PHASE4)
- Rapid Switch From Flolan to Remodulin in the Outpatient Clinic (PHASE4)
- Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |